Goldberg Law PC represents investors around the world, and specializes in securities class action lawsuits and shareholder rights litigation.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (Nasdaq: ICPT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between May 31, 2016, and September 20, 2017, inclusive (the "Class Period"), are encouraged to contact the firm before November 27, 2017, the lead plaintiff motion deadline. If you are a shareholder who suffered a loss during the Class Period, click here to participate. We also encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights free of charge. You can also reach us through the firm's website at http://www.goldberglawpc.com/, or by email at firstname.lastname@example.org. The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. The Complaint alleges that during the Class Period, Intercept made materially false and/or misleading statements, and/or failed to disclose, that its lead product candidate, Ocaliva, entailed undisclosed safety risks, including death, to patients suffering from primary biliary cholangitis ("PBC"). As a result, the Company's public statements were materially false and misleading at all relevant times. On September 12, 2017, Intercept issued a letter that warned physicians against overdosing patients with Ocaliva, advising them that the drug has been connected to liver injuries and death among patients suffering from PBC. On September 21, 2017, the U.S. Food & Drug Administration issued a safety announcement entitled "FDA Drug Safety Communication: FDA warns about serious liver injury with Ocaliva for rare chronic liver disease," warning doctors after reports of multiple deaths linked to the drug. Following this news, Intercept's stock price dropped materially, which caused investors harm.